Advocacy through groups like BCAN and the AUA shapes urologic oncology policy—driving funding, screening access, and equity in cancer care, the authors write.
Feature|Articles|July 1, 2025
FDA updates in urology: June 2025
Author(s)Hannah Clarke
Fact checked by: Benjamin P. Saylor, Strategic Content Lead
A recap of the FDA submissions and regulatory decisions in urology from June 2025.
Advertisement
Advertisement
Welcome to Urology Times’® monthly FDA update! June was a busy month for urological regulatory news, featuring new approvals for prostate cancer, bladder cancer, benign prostatic hyperplasia (BPH), and incontinence. Additionally, notable advancements were made in the development of an oral antibiotic for uncomplicated gonorrhea, a theranostic radiopharmaceutical in prostate cancer, and a gene-based immunotherapy in bladder cancer.
Related to this article
The PDUFA target action date is in the fourth quarter of 2026.
Positive safety and efficacy data from 4 clinical studies supported the CE marking.
Sandip Prasad, MD, discusses patient selection for chemoablation in recurrent LG-IR-NMIBC and considerations when counseling patients about a nonsurgical approach.
In a head-to-head RCT, Rezūm produced a 4.6-point greater IPSS improvement than combination pharmacotherapy at 1 year, according to Jean-Nicolas Cornu, MD, PhD, FEBU.
Better detection has changed prostate cancer care. Patients choosing radical treatment still need better protection from the disease returning.
Enfortumab vedotin-ejfv (Padcev) plus pembrolizumab (Keytruda) showed the strongest EFS, OS, and PCR associations among neoadjuvant MIBC strategies in a network meta-analysis, although perioperative design limits attribution.
Sandip Prasad, MD, MPhil, discusses the evolving role of chemoablation in recurrent low-grade, intermediate-risk NMIBC, including patient selection and treatment considerations.
Advertisement
Advertisement